Moderna, Inc.Long
Analysis on Moderna (Vaccine Company)
Moderna (MRNA) is developing a COVID-19 vaccine candidate that is widely considered one of the frontrunners to bring a vaccine to market; it was the first company to share data about how its experimental vaccine performed in a Phase 1 clinical trial. It has so far soared more than 350% since the start of the year. The main reason is that there has been tremendous widespread investor interest on their vaccination project, and the obvious unmet need/opportunity for a COVID-19 vaccine. However, J.P. Morgan just recently downgraded the rating on Moderna (MRNA) and signal that its currently overvalued. I feel that if the price dips or there's any pullback, would be a good opportunity to enter for a short hold and probably selling it upon the next peak which I believe would be around their Phase 3 trials. Because long term hold on Moderna might be risky since more often than not, vaccines usually takes a long time before it actually gets released and for the company to be actually profitable.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.